ym 529 has been researched along with etoposide in 1 studies
| Studies (ym 529) | Trials (ym 529) | Recent Studies (post-2010) (ym 529) | Studies (etoposide) | Trials (etoposide) | Recent Studies (post-2010) (etoposide) |
|---|---|---|---|---|---|
| 140 | 23 | 71 | 18,306 | 3,693 | 4,900 |
| Protein | Taxonomy | ym 529 (IC50) | etoposide (IC50) |
|---|---|---|---|
| nuclear receptor coactivator 1 isoform 1 [Homo sapiens] | Homo sapiens (human) | 1.153 | |
| nuclear receptor coactivator 3 isoform a | Homo sapiens (human) | 1.4284 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 3.187 | |
| Caspase-3 | Homo sapiens (human) | 1 | |
| DNA topoisomerase 2-beta | Homo sapiens (human) | 0.4299 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 4.18 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goto, H; Hanibuchi, M; Miki, T; Sone, S; Uehara, H; Yano, S; Zhang, H | 1 |
1 other study(ies) available for ym 529 and etoposide
| Article | Year |
|---|---|
Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Carcinoma, Small Cell; Cell Division; Diphosphonates; Drug Combinations; Etoposide; Humans; Imidazoles; Kidney Neoplasms; Killer Cells, Natural; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Mice; Mice, Inbred ICR; Mice, SCID; Osteoclasts; Parathyroid Hormone-Related Protein; Survival Rate; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2003 |